Warning, objects are closer than they appear; regarding our pre-clinical MASH study under SMC Laboratories with results late September, containing an arm with Madrigal’s drug, per our new hero doctor:

“CytoDyn’s CEO, Dr. Jacob Lalezari, stated, “in addition to clarifying dosing and efficacy, the goal of this study is to eventually use the results to pursue partnerships in the MASH space.”